1-10 of 10
Robert A Copeland, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Eytan M. Stein, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Michael Savona, MD, Raoul Tibes, MD, Jessica K Altman, Mojca Jongen-Lavrencic, MD PhD, Hartmut Döhner, Prof., Scott Armstrong, MD PhD, Roy M Pollock, PhD, Nigel J Waters, PhD, Michelle Legler, MSHS, Blythe Thomson, MD, Scott Daigle, Alice McDonald, Carly Campbell, Ed Olhava, Eric E Hedrick, MD, Bob Lowenberg, MDPhD, Robert A Copeland, PhD, Martin S. Tallman, MD
Journal: Blood
Blood (2014) 124 (21): 387.
https://doi.org/10.1182/blood.V124.21.387.387
Published: 2014
Journal Articles

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Elayne Penebre, PhD, Kristy G Kuplast, Christina R Majer, L. Danielle Johnston, MS, Nathalie Rioux, PhD, Michael Munchhof, PhD, Lei Jin, PhD, P. Ann Boriak-Sjodin, PhD, Tim J Wigle, PhD, Suzanne L Jacques, PhD, Kip A West, PhD, Trupti Lingaraj, Kimberly Stickland, PhD, Scott A Ribich, PhD, Alejandra Raimondi, MS, Margaret Porter-Scott, PhD, Nigel J Waters, PhD, Roy M Pollock, PhD, Jesse J Smith, PhD, Olena Barbash, PhD, Ryan G. Kruger, PhD, Robert A Copeland, PhD, Mikel P Moyer, PhD, Richard Chesworth, DPhil, Kenneth W Duncan, PhD
Journal: Blood
Blood (2014) 124 (21): 438.
https://doi.org/10.1182/blood.V124.21.438.438
Published: 2014
Journal Articles

Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

Nigel J Waters, PhD, Blythe Thomson, MD, Iain Gardner, PhD, Trevor N Johnson, PhD, Edward J Olhava, PhD, Roy M Pollock, PhD, Michelle Legler, MSHS, Robert A Copeland, PhD, Eric E Hedrick, MD
Journal: Blood
Blood (2014) 124 (21): 3619.
https://doi.org/10.1182/blood.V124.21.3619.3619
Published: 2014
Journal Articles

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models

L. Danielle Johnston, Sarah Knutson, PhD, Natalie Warholic, Christine R Klaus, Tim J. Wigle, PhD, Dorothy Iwanowicz, Bruce A. Littlefield, PhD, Margaret Porter Scott, PhD, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Roy M. Pollock, PhD, Kevin W Kuntz, PhD, Heike Keilhack, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 4416.
https://doi.org/10.1182/blood.V122.21.4416.4416
Published: 2013
Journal Articles

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL -Rearranged Leukemia Cells

Christine R Klaus, Scott R. Daigle, PhD, Dorothy Iwanowics, L. Danielle Johnston, Carly A Therkelsen, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Edward J Olhava, PhD, Margaret Porter Scott, PhD, Roy M. Pollock, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 3930.
https://doi.org/10.1182/blood.V122.21.3930.3930
Published: 2013
Journal Articles

Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics

Robert A. Copeland, PhD
Journal: Blood
Blood (2013) 122 (21): SCI-21.
https://doi.org/10.1182/blood.V122.21.SCI-21.SCI-21
Published: 2013
Journal Articles

Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL -Rearranged Leukemia.

Roy M Pollock, PhD, Scott R Daigle, Carly A Therkelsen, Aravind Basavapathruni, PhD, Lei Jin, PhD, Christina J Allain, Christine R Klaus, Alejandra Raimondi, PhD, Margaret Porter Scott, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD, Edward J Olhava, PhD
Journal: Blood
Blood (2012) 120 (21): 2379.
https://doi.org/10.1182/blood.V120.21.2379.2379
Published: 2012
Journal Articles

Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice

Heike Keilhack, PhD, Akira Yokoi, PhD, Sarah K Knutson, PhD, Tim Wigle, PhD, Natalie Warholic, Satoshi Kawano, PhD, Yukinori Minoshima, PhD, Kuan-Chun Huang, PhD, Galina Kuznetsov, PhD, Namita Kumar, Christine R Klaus, Christina J Allain, Alejandra Raimondi, PhD, Margaret Porter Scott, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Toshimitsu Uenaka, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD, Roy M Pollock, PhD, Kevin W Kuntz, PhD
Journal: Blood
Blood (2012) 120 (21): 3712.
https://doi.org/10.1182/blood.V120.21.3712.3712
Published: 2012
Journal Articles

Lymphoma-Associated Mutations of EZH2 Result In a Change-of-Function

Victoria M Richon, PhD, Christopher J Sneeringer, MSc, Margaret Porter Scott, PhD, Kevin W Kuntz, PhD, Sarah K Knutson, PhD, Roy M Pollock, PhD, Robert A Copeland, PhD
Journal: Blood
Blood (2010) 116 (21): 707.
https://doi.org/10.1182/blood.V116.21.707.707
Published: 2010
Journal Articles

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Roy M Pollock, PhD, Scott R Daigle, Edward J Olhava, PhD, Carly A Therkelsen, Christina R Majer, Jeffrey Song, Christina J Allain, Christopher J Sneeringer, L. Danielle Johnston, Margaret Porter Scott, PhD, Lei Jin, PhD, Kevin W Kuntz, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Kathrin M Bernt, MD, Scott Armstrong, MD, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD
Journal: Blood
Blood (2010) 116 (21): 780.
https://doi.org/10.1182/blood.V116.21.780.780
Published: 2010